ARTICLE | Company News
Replidyne, Daiichi Sankyo, Nippon Soda Co. Ltd. deal
June 30, 2008 7:00 AM UTC
Replidyne terminated its 2004 license agreement with Daiichi Sankyo’s Asubio Pharma Co. Ltd. subsidiary that gave Replidyne exclusive North American rights to develop and commercialize Asubio’s faropenem medoxomil to treat community-acquired infections (see BioCentury, Aug. 23, 2004). Replidyne said it was unable to secure a partner for the ester prodrug derivative of paropenem, prompting the termination. The company will pay a license termination fee of up to ¥375 million ($3.5 million) to Asubio. ...